XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.19.1

Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($) $ in Millions | 3 Months Ended |
--- | --- | ---
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018
Other current assets | AstraZeneca |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Receivables from counterparty | $ 80 |  | $ 52
Other current assets | Eisai |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Receivables from counterparty | 75 |  | 71
Other current assets | Bayer AG |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Receivables from counterparty | 33 |  | 32
Accounts payable and accrued liabilities | AstraZeneca |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Payables to counterparty | 584 |  | 405
Accounts payable and accrued liabilities | Eisai |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Payables to counterparty | 557 |  | 375
Other noncurrent liabilities | AstraZeneca |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Payables to counterparty | 0 |  | 250
Other noncurrent liabilities | Eisai |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Payables to counterparty | 325 |  | 543
Other noncurrent liabilities | Bayer AG |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Payables to counterparty | 375 |  | $ 375
Revenue | AstraZeneca |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Total sales | 79 | $ 33 |
Revenue | Eisai |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Total sales | 74 | 0 |
Revenue | Bayer AG |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Net product sales recorded by Merck | 48 | 43 |
Merck’s profit share from sales in Bayer’s marketing territories | 42 | 25 |
Total sales | 90 | 68 |
Cost of sales | AstraZeneca |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 19 | 12 |
Cost of sales | Eisai |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 51 | 0 |
Cost of sales | Bayer AG |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 29 | 27 |
Selling, general and administrative | AstraZeneca |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 27 | 7 |
Selling, general and administrative | Eisai |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 19 | 0 |
Selling, general and administrative | Bayer AG |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 8 | 8 |
Research and development | AstraZeneca |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 45 | 29 |
Research and development | Eisai |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | 47 | 1,400 |
Research and development | Bayer AG |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Expenses | $ 30 | $ 28 |

X
- Definition Collaborative Arrangement, Expenses + References No definition available. + Details
Name: | mrk_CollaborativeArrangementExpenses
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Payable + References No definition available. + Details
Name: | mrk_CollaborativeArrangementPayable
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Profit Sharing + References No definition available. + Details
Name: | mrk_CollaborativeArrangementProfitSharing
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Receivable + References No definition available. + Details
Name: | mrk_CollaborativeArrangementReceivable
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Revenues, Net of Commercialization Costs + References No definition available. + Details
Name: | mrk_CollaborativeArrangementRevenues
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Sales, Net + References No definition available. + Details
Name: | mrk_CollaborativeArrangementSalesNet
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_EisaiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_BayerAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |